<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Targeting steroid-metabolizing enzymes with 15β-substituted estrone analogues</dc:title><dc:creator>Resch,	Vivien	(Avtor)
	</dc:creator><dc:creator>Gjorgoska,	Marija	(Avtor)
	</dc:creator><dc:creator>Hafner,	Eva	(Avtor)
	</dc:creator><dc:creator>Bacsa,	Ildikó	(Avtor)
	</dc:creator><dc:creator>Kovács,	Benjamin	(Avtor)
	</dc:creator><dc:creator>Büdefeld,	Tomaž	(Avtor)
	</dc:creator><dc:creator>Hunyadi,	Attila	(Avtor)
	</dc:creator><dc:creator>Huliák,	Ildikó	(Avtor)
	</dc:creator><dc:creator>Kiricsi,	Mónika	(Avtor)
	</dc:creator><dc:creator>Paragi,	Gábor	(Avtor)
	</dc:creator><dc:creator>Lanišnik-Rižner,	Tea	(Avtor)
	</dc:creator><dc:creator>Mernyák,	Erzsébet	(Avtor)
	</dc:creator><dc:subject>17β-HSD1 enzyme</dc:subject><dc:subject>AKR1C1–3 enzymes</dc:subject><dc:subject>antiproliferative</dc:subject><dc:subject>chemoresistance</dc:subject><dc:subject>fluorescent labeling</dc:subject><dc:subject>inhibitor</dc:subject><dc:description>Background/objectives: Aldo-keto reductase isoforms AKR1C1-3 and 17β-hydroxysteroid dehydrogenase 1 and 2 (17β-HSD1 and 17β-HSD2) are key enzymes in steroid metabolism and validated targets in hormone-dependent cancers. 
Methods: In this study, Δ15- and 15β-substituted estrone derivatives were evaluated as inhibitors of AKR1C1-3 and 17β-HSD1 using enzymatic assays, cell viability assaysand computational modeling. Cellular uptake of the fluorescent estrone-based inhibitor was investigated using confocal microscopy. 
Results: The Δ15-estrone derivative showed potent and selective inhibition of 17β-HSD1 in the low nanomolar range, while 15β-O-propargyl and 15β-azide derivatives exhibited dual inhibitory activity against 17β-HSD1 and AKR1C2. The Δ15- and 15β-azide derivatives reduced cell viability in hormone-dependent breast, endometrial, and ovarian cancer cell lines in the sub- to low-micromolar range. A BODIPY-labeled 15β-O-propargyl analogue retained submicromolar inhibitory potency toward 17β-HSD1, representing the first fluorescent estrane-based inhibitor with preserved biological activity. Confocal microscopy confirmed efficient cellular uptake and predominant cytosolic localization in MCF-7 cells. 
Conclusions: These findings identify Δ15- and 15β-modified estrone derivatives as promising single- and dual-target inhibitors and introduce a fluorescent probe suitable for investigating intracellular steroid metabolism in hormone-dependent malignancies.</dc:description><dc:date>2026</dc:date><dc:date>2026-07-06 10:00:29</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>184373</dc:identifier><dc:identifier>UDK: 577.2</dc:identifier><dc:identifier>ISSN pri članku: 2072-6694</dc:identifier><dc:identifier>DOI: 10.3390/cancers18121889</dc:identifier><dc:identifier>COBISS_ID: 283168259</dc:identifier><dc:language>sl</dc:language></metadata>
